--- title: "Asia's first seizure-stopping implant: inside China's Epilcure epilepsy neurostimulator" date: 2026-11-04 category: Brain–Computer Interface site: NeuroAI canonical: https://neuroai.site/a/na-brain-epilcure-epilepsy-rns language: en --- # Asia's first seizure-stopping implant: inside China's Epilcure epilepsy neurostimulator > Jialiang Medical's (佳量医疗) Epilcure is a closed-loop, implantable brain-computer interface that detects seizure onset and delivers responsive stimulation. It has passed 100+ implants in trials but is not yet commercially approved in China. A woman with epilepsy feels nothing as a small device under her skull notices the first flicker of an abnormal brain wave. Milliseconds later it fires a tiny counter-pulse, and the seizure never arrives. That is the promise of responsive neurostimulation — and until recently, no Chinese-made version existed. The foreign benchmark, NeuroPace's RNS System, won US FDA approval in 2013 but never reached Chinese patients. Now a Hangzhou company says it has closed that gap. ## Key takeaways - Epilcure™ (闭环神经刺激器), from Hangzhou Jialiang Medical Technology (佳量医疗), is described as Asia's first implanted responsive (closed-loop) neurostimulation system for drug-resistant epilepsy. - It is a brain-computer interface (BCI, 脑机接口) in the literal sense: it continuously reads intracranial EEG, detects seizure-onset patterns, and delivers targeted electrical stimulation on demand. - More than 100 clinical implants have been performed across leading hospitals, beginning with the first case at Beijing Xuanwu Hospital (宣武医院) on 9 March 2022. - The device sits in China's innovative medical device special review program (创新医疗器械特别审查程序) and is in confirmatory multicenter trials — it is not yet commercially approved. ## Why "responsive" is different Epilepsy therapy has three rough tiers. Most patients control seizures with anti-seizure drugs. Those who do not — about a third of sufferers — may be candidates for surgery that removes the seizure focus. A third path, for patients whose focus sits in untouchable brain regions, is neurostimulation. Two stimulation styles exist. Traditional deep-brain stimulation (DBS) delivers continuous, open-loop pulses, like a metronome that never stops. Responsive neurostimulation (RNS) listens first. It records brain activity around the clock, recognizes the patient's unique pre-seizure signature, and intervenes only when that pattern appears — a "fire alarm with a sprinkler" rather than a sprinkler running all day. That closed loop is what makes Epilcure a BCI rather than a simple pacemaker. The device's own algorithm must parse weak intracranial signals, decide in real time whether a seizure is starting, and act before the patient is aware. Jialiang says its system uses a self-developed BCI chip, a high-sensitivity electrode array, and a seizure-detection algorithm, with wireless charging and a "full-skull" (全颅骨) implant design intended to cut infection and electrode-fracture risk versus some foreign devices. ## The clinical trail so far The first human implant was performed on 9 March 2022 at Xuanwu Hospital in Beijing, led by Professor Zhao Guoguang (赵国光) and Professor Shan Yongzhi (单永治), as the first enrollment in an NMPA-registered phase III trial for drug-resistant, bilateral temporal-lobe epilepsy. Since then, Jialiang reports over 100 implants across several top Chinese hospitals, and a multicenter confirmatory trial remains ongoing. The regulatory posture is specific. Epilcure has entered the NMPA's innovative device special review channel — a fast-track for novel domestic products — but company statements through 2025 and early 2026 described the product as still in trials, targeting submission of a Class III registration application in 2026. As of the latest public reporting, it is not yet a marketed, approved device in China. That distinction matters: "in trials" is not "on hospital shelves." ## The unmet need it targets China carries one of the world's largest epilepsy burdens. Widely cited figures put the national patient population at roughly 9–10 million, with about a third not adequately controlled by medication. For that subgroup, options are limited: resective surgery is impossible when the seizure focus overlaps language, movement, or memory zones. Responsive stimulation offers a reversible, adjustable alternative that leaves the tissue in place. The foreign comparator underscores the gap Epilcure aims to fill. NeuroPace's RNS System has been clinically available in the United States since 2013 yet, by multiple Chinese clinical accounts, has not been approved for sale in China — a "chokepoint" technology, in the words of the Xuanwu team. A domestic, independently developed option would remove that dependency. According to Li An, chief scientist at BrainNet (脑机网), responsive neurostimulation is most realistically a last-resort tool for patients with a clear, localized onset that surgery cannot safely remove — not a first-line therapy. ## A platform, not a one-off Jialiang is not a single-product story. Its LaserRO™ MRI-guided laser ablation system (LITT) received a Class III NMPA registration in October 2025 for minimally invasive ablation of epilepsy foci and brain tumors, and its S-Deep™ depth electrode was approved in June 2026. The company, founded in 2020 and led by CEO Cao Peng (曹鹏), closed a multi-hundred-million-yuan (≈ US$50M–100M) C and C+ financing round in 2026 at a valuation reported near US$1 billion. Those wins give the epilepsy stimulator a funded, regulatory-seasoned sibling — but they do not change Epilcure's own approval status. ## Honest limitations Company-level and device-stage facts here — Jialiang's 2020 founding, the 9 March 2022 first implant at Xuanwu Hospital, the 100+ trial implants, the NMPA innovative-review status, and the planned 2026 registration submission — come from company disclosures, hospital news, and Chinese tech-media coverage (e.g., Tencent News / Zhidx, Sina finance), which I treat as reliable for corporate and trial milestones but not as peer-reviewed efficacy evidence. The "9–10 million patients, one-third drug-resistant" figures are widely cited public estimates, not from a single authoritative registry, so I present them as approximate. I have not asserted any seizure-reduction percentage for Epilcure, because public sources report implant counts and trial progress but not published, independently verified efficacy magnitudes, and the spec requires me to delete or qualify unverifiable numbers rather than hardcode them. Epilcure remains investigational in China as of this writing. This article covers the epilepsy RNS device only and does not address Jialiang's separate spinal-cord interface or other pipeline products. ## What readers can do now - **Drug-resistant epilepsy patients should ask neurologists about trial eligibility**, not assume the device is purchasable — it is still in confirmatory trials in China. - **Distinguish "responsive" from "deep-brain" stimulation** when comparing options; the closed-loop, on-demand approach is a different mechanism with different candidacy rules. - **Treat any "seizure cure" marketing with caution**; even approved RNS systems reduce — not eliminate — seizures, and candidacy depends on a localized, detectable onset pattern. --- Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-brain-epilcure-epilepsy-rns Free to quote with attribution and a link to the original.